Continuum DAP 3-Year DOI (Canada)

This page contains information on Continuum DAP 3-Year DOI for veterinary use.
The information provided typically includes the following:
  • Continuum DAP 3-Year DOI Indications
  • Warnings and cautions for Continuum DAP 3-Year DOI
  • Direction and dosage information for Continuum DAP 3-Year DOI

Continuum Dap 3-year Doi

This treatment applies to the following species:
Manufacturer: Merck Animal Health

Canine Distemper-adenovirus Type 2-parvovirus Vaccine

Modified Live Virus

Product Description: Continuum™ Dap Is A Modified Live Virus Vaccine Containing Attenuated Strains Of Canine Distemper Virus (cdv), Adenovirus Type 2 (cav-2), And Parvovirus (cpv). continuum™ Dap Is Presented In A Desiccated Form With Sterile Diluent Provided For Reconstitution. The Attenuated Distemper Virus Strain Used In continuum™ Dap Is The Onderstepoort Strain. The Parvovirus Component Is Patented* cpv Strain 154® Which Is An Attenuated Parvovirus Strain Of Canine Origin. continuum™ Dap Is Produced With High Titered Cpv And Cdv Components Which Are Immunogenic. The Manhattan Strain Of Adenovirus Type 2 In continuum™ Dap Confers Protection Against Canine Infectious Hepatitis Caused By Cav-1 Without The Adverse Reactions Associated With Cav-1, Such As Corneal Edema (“blue Eye”).

indications

For the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, canine adenovirus type-1, and canine parvovirus for up to 3 years following initial and booster vaccinations. Protection against CAV-2 was demonstrated by serological responses in dogs at 36 months following vaccination.

Safety Data

Extensive safety testing has demonstrated that CPV STRAIN 154® and the distemper component of CONTINUUM™ DAP are safe when given to puppies as young as 4 weeks of age.

Efficacy Data

Seronegative pups, vaccinated at 7 and 11 weeks of age were held in strict isolation for 3 years (36 months) following the last vaccination and then challenged with virulent CAV-1, CPV and CDV. Serum antibody titers for CAV-2, CDV, and CPV were measured throughout the isolation period (Table 1). The geometric mean antibody titers (GMT) remained at high levels throughout the isolation period.

Table 1. Geometric mean titers (GMT) in dogs following second vaccination with CDV, CAV-2, and CPV.

Virus Fraction (Assay)

Pre-
vac

Months After Vaccination

1

3

6

9

12

21

24

30

33

36

CAV2 (SN)

<2

89

153

964

497

672

368

379

332

256

357

CDV (SN)

<2

402

781

195

110

241

201

48

144

100

193

CPV (HI)

<10

567

680

1444

395

640

350

257

192

151

237

At 36 months post vaccination, the GMT for CAV-2 was 1:357, for CDV was 1:193, and for CPV was 1:237. Thirty-six months following vaccination, the dogs were challenged sequentially with virulent CAV-1 (Mirandola strain, IV challenge), CPV (CPV-2b field isolate, oral/nasal challenge) and CDV (Snyder Hill strain, intracranial challenge). For each virus challenge, 6 age-matched, nonvaccinated control pups were also challenged. Control dogs were not challenged sequentially.

Cav-1 Challenge

Severe clinical signs of CAV-1 including depression, diarrhea, increased water consumption, anorexia, corneal opacity, and vomiting were seen in 5 (83%) of the 6 control dogs. One control dog died prior to developing clinical signs. Three (50%) of the 6 control dogs died following CAV-1 challenge. Clinical signs of CAV-1 infection were prevented in 100% of the vaccinated dogs (Table 2).

Table 2. Cav-1 Challenge

treatment

Dogs

Signs*

Temp

death

Total # Dogs Sick

CONTINUUM™ DAP

23

0

0

0

0/22§

Control

6

5

4

3

6/6

* Depression, diarrhea, increased water consumption, anorexia, corneal opacity, vomiting.

T ≥103.4°F

§ One vaccinated dog died 3 days after challenge due to physical injury.

For CAV-2, a 3-year duration of immunity is supported by data demonstrating a robust serologic response to CAV-2 through the 36-month postvaccination period and a strong cross-protection against a heterologous CAV-1 challenge.

Cpv Challenge

Following CPV-2b challenge, all 6 control dogs exhibited lymphopenia and severe clinical signs of CPV (including depression, diarrhea, dehydration, anorexia, vomiting, and pyrexia) lasting between 3-11 days duration. Two (33%) of the 6 control dogs died following challenge (Table 3). Fecal samples were evaluated for virus isolation using standard hemagglutination (HA) methods. Dogs with viral hemagglutinins at a level of ≥ 1:64 in a 1:5 dilution of feces were considered to be infected and shedding virulent CPV virus. All of the control dogs excreted virulent CPV virus in their feces; whereas none of the vaccinates excreted virus. Eight of the 22 vaccinated dogs had infrequent clinical signs that were of short duration (≤2 days) and noncontiguous events. Although clinical signs resulting from CPV-2b infections characteristically appear between 4-5 days post challenge, diarrhea and vomiting were reported as early as 1 day post challenge in some of the vaccinated dogs. Clinical signs required for CPV infection were prevented in 100% of the vaccinated dogs.

Table 3. Cpv-2b Challenge.

treatment

Dogs

Positive Virus Isolation

Lymphopenia
≥ 50%
baseline Value

Clinical Signs
(# Days Sick)*

death

CONTINUUM™ DAP

22

0

0

8 (≤2)

0

Control

6

6

6

6 (3-11)

2

* Depression, diarrhea, dehydration, anorexia, vomiting, pyrexia

Cdv Challenge

For the CDV challenge, 3 control groups were used to evaluate the severity of the challenge. These included the 6 age-matched controls challenged with the full challenge dose, 5 seronegative, 10- to 12-week-old pups challenged with the full challenge dose, and 5 seronegative, 10- to 12-week-old pups challenged with 1/10th of the challenge dose. Pups were challenged in addition to the age-matched adults since older dogs are more resistant to challenge. Severe clinical signs of CDV including depression, dehydration, salivation, apprehension, diarrhea, anorexia, inability to rise, pyrexia, tremor, and vomiting were seen in 100% of the control dogs in all groups. Two (33%) of the age-matched control dogs, 5 (100%) of the 12-week-old pups challenged with the full challenge dose, and 4 (80%) of the 12-week-old pups challenged with 1/10th of the challenge dose died following challenge. Clinical signs of CDV infection were prevented in 100% of the vaccinated dogs (Table 4).

Table 4. Cdv Challenge.

treatment

Dogs

Signs*

Death

% Dead

CONTINUUM™ DAP

22

0

0

0

Adult Control

6

6

2

33

Puppy Control

5

5

5

100

Puppy Control
(diluted challenge)

5

5

4

80

* Depression, dehydration, salivation, apprehension, diarrhea, anorexia, unable to rise, pyrexia, tremor, vomiting

Diluted challenge was 1:10 dose of standard challenge

The prevented fraction of CONTINUUM™ DAP was determined for each of the fractions evaluated by challenge (Table 5). The prevented fraction is the proportion of infection prevented by the vaccine relative to the infection rate in nonvaccinated dogs. The prevented fractions were greater than 95% for all challenges.

Table 5. Prevented Fraction.

fraction

Continuum™ Dap

Prevented Fraction

95% Confidence Interval

CAV-2 (ICH)

96%

79%, 100%

CDV

100%

85%, 100%

CPV

100%

85%, 100%

The results of these studies demonstrate that the modified-live viruses in CONTINUUM™ DAP provide protection against virulent CAV-1, CPV, and CDV challenges in 7-weeks-of-age or older dogs for a minimum of 3 years following second vaccination.

Directions For Use

Aseptically reconstitute the desiccated vaccine with the sterile diluent provided and administer 1 mL by the subcutaneous route. Initial vaccination of healthy dogs may be given as early as 6 weeks of age, with booster injections administered every 3-4 weeks until 12 weeks of age. Dogs over 12 weeks of age should initially receive 2 doses 3-4 weeks apart. Revaccinate every three years with a single dose thereafter.

Precautions

1. Recommended storage temperature 2-7°C (35-45°F). Do not freeze.

2. Shake well before use.

3. Use contents promptly once reconstituted.

4. Non-chemically sterilized needles and syringes should be used for administration of vaccine.

5. Avoid vaccinating pregnant bitches.

6. Administration of epinephrine may be indicated in the event of an anaphylactic reaction.

7. Contains gentamicin as a preservative.

8. Burn this container and all unused contents.

9. Only healthy animals should be vaccinated. Animals incubating any disease or animals stressed due to shipping, malnutrition, or parasitism may not achieve or maintain an adequate immune response.

10. This product is not hazardous when used according to directions supplied. A material safety data sheet (MSDS) is available upon request. This and any other consumer information can be obtained by calling toll free Intervet Canada Corp. Customer Service at 1-866-683-7838.

Supplied

Cartons of 25 1-dose/1-mL desiccated vaccine vials and 25 1-mL sterile diluent vials. Packaged in recyclable plastic containers.

Sales Product Code

006772

For Veterinary Use Only

U.s. Veterinary License No. 165a

Intervet Inc., Millsboro, De 19966

For technical enquiries, call toll free 1 888 306-0069.

™Trademark of Intervet International B.V., used under license by Intervet Canada Corp.

*U.S. Patent No. 4,810,494 and 5,316,764

Rev. 900602

AL 400

Nac No.

12081893
MERCK ANIMAL HEALTH
Intervet Canada Corp.

16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
Order Desk:   514-428-7013
Toll-Free:   866-683-7838
Fax:   Toll-free 888-498-4444; local 514-428-7014
Website:   www.merck-animal-health.ca
Every effort has been made to ensure the accuracy of the Continuum DAP 3-Year DOI information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-05-28

(web5)